Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
The world's largest healthcare company is making shrewd investments in its future.
Nvidia CEO Jensen Huang has stated that the most profound impact of artificial intelligence (AI) will be in the life sciences industry. One company that stands to benefit from AI is Eli Lilly (LLY), according to the report. The drug discovery and development process is expensive, lengthy, and risky, with most compounds failing to reach the market.
Eli Lilly has addressed this issue by building LillyPod, a supercomputer focused on AI in drug discovery. However, the effectiveness of AI models in drug discovery depends on the quality of data used to train them, and Eli Lilly possesses vast amounts of data on clinical trial successes and failures in diabetes and weight-loss markets, which gives it a competitive advantage.
Despite this, other pharmaceutical giants like Novo Nordisk, AbbVie, and Bristol Myers Squibb are also investing heavily in AI. The article concludes by highlighting Eli Lilly's excellent financial results, promising pipeline of products, and solid dividend stock, making it a potential buy for growth and income-oriented investors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
